Drugs Made In America Acquisition DMAA
NASDAQ DMAA
$10.80 +0.01 (+0.09%)
At close: Sep 9, 2026 · 4:00 PM EDT

Drugs Made In America Acquisition (DMAA) Operating Income (2025 - 2026)

Drugs Made In America Acquisition's (DMAA) quarterly Operating Income came in at -$136934.0 in Q2 2026, down 3.8% on a YoY basis from -$142345.4 in Q2 2025, and up 93.45% quarter-over-quarter from -$2.1 million in Q4 2025.

Analysis

Drugs Made In America Acquisition (DMAA) Operating Income (2025 - 2026) Analysis & Trends

Drugs Made In America Acquisition (DMAA) has reported Operating Income for 2 consecutive years, with -$136934.0 the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Operating Income fell 3.8% year-over-year to -$136934.0; the trailing twelve-month figure through Jun 2026 stood at -$2.6 million (changed N/A YoY), and the FY2025 full-year result was -$2.8 million, down 906.28% from the prior year.
  • Operating Income climbed to -$136934.0 in Q2 2026 per DMAA's latest filing, from -$2.1 million in the prior quarter.
  • Across five years, Operating Income topped out at -$131919.0 in Q2 2025 and bottomed at -$2.1 million in Q4 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Op. Inc (Qtr)
1 Blackstone 103.57 Bn 101.06 Bn - -
2 Kkr 93.46 Bn -183.61 Bn - 2.04 Bn
3 Apollo Global Management 77.60 Bn 52.22 Bn 10.54 Bn 5.35 Bn
4 Brookfield Asset Management 76.45 Bn 74.94 Bn - -
5 Wheaton Precious Metals 71.34 Bn 71.24 Bn 687.86 Mn 667.06 Mn
6 Franco Nevada 51.21 Bn 49.67 Bn 451.00 Mn 445.70 Mn
7 Brookfield 37.98 Bn 7.42 Bn 19.38 Bn 34.32 Bn
8 Ares Management 30.49 Bn 30.49 Bn - -
9 Carlyle 15.82 Bn 14.57 Bn - -
10 Drugs Made In America Acquisition 332.77 Mn 332.77 Mn - -136,934.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -136,934.00
Dec 31, 2025 -2.09 Mn
Sep 30, 2025 -263,703.00
Jun 30, 2025 -131,919.00
Mar 31, 2025 -330,925.00